Key points are not available for this paper at this time.
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most used 177LuLu-PSMA RPT compounds. Methods: This was a systematic review and metaanalysis of 177LuLu-PSMA RPT (617, I P = 0.26). Dosimetry data of 177LuLu-J591 were limited to one published study of 35 patients with reported absorbed doses of 1.41, 0.32, and 2.10 Gy/GBq to the kidney, bone marrow, and liver, respectively. Conclusion: In this metaanalysis, there was no significant difference in absorbed dose between 177LuLu-PSMA-I&T and 177LuLu-PSMA-617. There was a possible trend toward a higher kidney dose with 177LuLu-PSMA-I&T and a higher tumor lesion dose with 177LuLu-PSMA-617. It remains unknown whether this finding has any clinical impact. The dosimetry methodologies were strikingly heterogeneous among studies, emphasizing the need for standardization.
Ells et al. (Wed,) studied this question.